Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector

Project Information

GENEGRAFT

Grant agreement ID: 261392

Project closed

Start date 1 March 2011

End date 31 December 2017

Funded under

• Specific Programme "Cooperation": Health

Total cost € 6 584 623,18

EU contribution € 4 961 654,00

Coordinated by

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France